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such changes were not ameliorated either by ACE inhibitionGlomerular size-selective dysfunction in NIDDM is not amelio-
or calcium channel blockade.rated by ACE inhibition or by calcium channel blockade.
Background. In patients with insulin-dependent diabetes
mellitus (IDDM) and overt nephropathy glomerular barrier
size-selectivity progressively deteriorates with time and is effec- Studies of the glomerular sieving functional proper-tively improved by angiotensin converting enzyme (ACE) inhi-
ties in patients with insulin-dependent diabetes mellitusbition. Whether similar glomerular functional changes develop
(IDDM), clinical proteinuria and biopsy findings of dia-in proteinuric patients with non-insulin–dependent diabetes
mellitus (NIDDM), and whether antihypertensive agents can betic-type glomerulopathy (overt nephropathy) provided
favorably affect glomerular filtration of macromolecules in solid evidence of loss of size-selective properties of the
these patients, has not been documented yet. glomerular membrane, which appears a major determi-Methods. We investigated renal hemodynamics and frac-
nant of abnormal filtration of plasma proteins [1–4].tional clearance of neutral dextrans of graded sizes, in nine
Whether charge-selective dysfunction also occurs and toproteinuric patients with NIDDM and renal biopsy findings of
typical diabetic glomerulopathy. Six healthy volunteers served what extent it may play a role in abnormal permeability
as controls. We also investigated the effects of an ACE inhibitor to albumin and other proteins is less clear, partly due
and of a calcium channel blocker, both given in doses targeted to technical difficulties in measuring glomerular charge-to achieve a comparable level of systemic blood pressure con-
selective function in humans [4, 5]. In diabetic as introl, on glomerular hemodynamics and sieving function. Theo-
nondiabetic proteinuric nephropathies, plasma proteins,retical analysis of glomerular macromolecule transport was
adopted to evaluate intrinsic glomerular membrane permeabil- ultrafiltered in exuberant amount and reabsorbed by the
ity properties. proximal tubule, up-regulate inflammatory and vaso-
Results. Fractional clearance of large macromolecules (42 active genes whose protein products trigger an interstitialto 66 A˚ in radius) was significantly higher in diabetic patients
inflammatory reaction that culminates in renal scarringthan in controls, and the distribution of membrane pore radii
[6, 7].was calculated to be shifted towards larger pore sizes in diabet-
ics (mean radius increased from 55 to 60 A˚). Despite effective Theoretical analysis of glomerular sieving coefficients
blood pressure control, neither antihypertensive affected glo- of neutral test macromolecules indicated that in patients
merular hemodynamics to any significant extent. Fractional with IDDM, who were studied early in the course of theclearance of dextrans, as well as of albumin and IgG, and total
disease, angiotensin converting enzyme (ACE) inhibitionurinary proteins were not modified by either treatments.
reduced proteinuria by reducing the size of large unselec-Conclusions. These data indicate that patients with NIDDM
and overt nephropathy develop abnormalities in size-selective tive pores assumed to perforate the glomerular membrane
function of the glomerular barrier and, at variance to IDDM, [8]. IDDM patients benefitted from ACE inhibition even
when they were in an advanced stage of the nephropathy.
Data are indeed available showing the amelioration of
Key words: dextran, glomerular sieving, proteinuria, non-insulin–
glomerular barrier function and protein excretion evendependent diabetes mellitus, angiotensin converting enzyme, blood
pressure. independently from changes in systemic blood pressure
and renal hemodynamic parameters [9]. Moreover, ex-
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lar filtration rate (GFR) decline in patients with IDDM treated mild-to-moderate hypertension and diabetic ne-
phropathy diagnosed on the basis of the following: (1)and overt nephropathy [10]. The results of several clinical
studies have consistently indicated that among other anti- urinary protein excretion rate $ 0.5 g/24 hr on at least
three consecutive occasions before study entry; (2)hypertensives ACE-inhibitors, in addition to blood pres-
sure control, reduce urinary protein excretion and pre- changes in creatinine clearance , 30% over the last three
months; and (3) biopsy-proven diabetic glomerulopathy.vent renal injury and progression to end-stage renal
failure [11]. On the other hand, agents that fail to reduce At entry HbA1c was ,10% and all the patients had clini-
cally stable diabetes (that is, changes in HbA1c , 630%urinary proteins (namely nifedipine and other dihydro-
pyridinic calcium channel blockers) were unable to block as compared to HbA1c values four months before selec-
tion), stable body weight (changes in body weight , 65renal disease progression; instead their use appears to
be consistently associated with a fast rate of GFR decline kg as compared to the body wt 6 months before selection)
and were on constant treatment with diet and/or oral[12].
At variance with IDDM, information on glomerular antidiabetic agents and/or insulin for at least two months.
Serum potassium ranged between 3.5 and 5.0 mm/liter.permselective function in patients with non-insulin–
dependent diabetes mellitus (NIDDM) with overt ne- Pregnant or potentially child-bearing women with no
effective contraception treatment and nursing womenphropathy are missing, and the only available study was
done in a group of Pima Indian Americans who hap- were excluded. Patients with urinary tract infection, sec-
ondary hypertension, renovascular disease, solitary kid-pened to have a rather preserved GFR [13]. One expla-
nation for the lack of data on this condition is that precise ney or renal disease other than diabetic glomerulopathy,
heart failure (NYHA class III-IV), atrio-ventricularcharacterization of the nature of renal disease in
NIDDM with overt nephropathy poses some difficulties. block grade 2–3, stroke or acute myocardial infarction
in the last three months, symptomatic coronary ischemicIn a recent paper we found rather heterogeneous renal
biopsy findings in NIDDM that included at least three disease, liver or hematologic disease, collagen vascular
disease, cancer, chronic treatment with cimetidine, ste-distinct patterns of injury classified as diabetic-type
glomerulopathy, prevailing nephroangiosclerosis-type roidal and nonsteroidal treatment in the two months
before screening evaluation, known or suspected intoler-changes and lesions of nondiabetic glomerulopathy su-
perimposed to classical features of diabetes [14]. These ance to the study drugs, and any condition that in the
investigator’s judgment could interfere with the resultsdiverse patterns of lesions could potentially account for
different manifestations of glomerular barrier dysfunc- of the study were excluded. In particular, all potentially
eligible patients had an ultrasound evaluation performedtion and different responses to antihypertensive thera-
pies. before study entry and those with echographic evidence
of a postvoiding urine retention suggestive for obstruc-The purpose of the present study was to investigate
renal hemodynamics and glomerular barrier function in tive uropathy and/or bladder (dysautonomic) dysfunc-
tion were not included.Caucasian proteinuric NIDDM patients with biopsy evi-
dence of pure diabetic-type glomerular structural lesions. Pathological evaluations of kidney biopsies before en-
tering into the study revealed typical findings of diabeticWe also explored the possibility of modulating intrinsic
glomerular barrier properties by either an ACE inhibitor glomerulopathy consisting of marked glomerular hyper-
trophy associated with glomerulosclerosis, both of theor by a calcium channel blocker given in doses targeted
to achieve a comparable level of systemic blood pressure diffuse and nodular types, and diffuse arteriolar hyalino-
sis. Global glomerulosclerosis was observed in most pa-control.
tients (affecting on average 33% of glomeruli). All speci-
mens exhibited thickening of glomerular capillary wall
METHODS
and of Bowman’s capsule, interstitial fibrosis and thick-
Study population ening of tubular basement membrane. Electron micros-
copy examinations displayed typical changes of diabeticStudy patients were selected among a pool of 52
NIDDM patients (30 males and 22 females) referred to nephropathy characterized by a marked and diffuse
thickening of glomerular basement membrane and dif-the Unit of Nephrology and Dialysis of the Azienda Ospe-
daliera, Ospedali Riuniti di Bergamo from April 1983 to fused sclerotic changes. Six male normotensive volunteers
with no sign of renal disease served as healthy controlsNovember 1991 who had a renal biopsy performed to
investigate the causes of persistent clinical proteinuria (Table 1). All subjects gave informed consent before
being allowed to enter the study.and/or renal insufficiency [14]. Among these, 12 subjects
satisfied the inclusion/exclusion criteria detailed in the
Study designstudy protocol and 9 (8 males and 1 female) provided
their informed consent according to the Declaration of This was a double-blind sequential study (Fig. 1) with a
placebo run-in phase followed by two treatment periods,Helsinki. The patients had newly diagnosed or previously
Ruggenenti et al: Glomerular size-selective dysfunction in NIDDM986
Table 1. Main clinical and laboratory findings in healthy controls performed at 8 and at 10 weeks of each treatment period,
and in NIDDM patients at baseline evaluation
and the mean of two determinations was used for statisti-
Healthy cal analysis.
Parameter controls NIDDM The study protocol was approved by the Italian Health
Age year 26 (24–27) 64 (51–72)b Authorities (Ministero della Sanita`, Direzione Generale
Sex M/F 6/0 8/1
del Servizio Farmaceutico) and by the Ethical Commit-Diabetes duration year — 12.6 (1–25)
Hypertension duration year — 3.6 (0.3–11) tee of the Regione Lombardia.
SBP mm Hg 12869 167 611b
DBP mm Hg 6967 99 67b Functional studiesBody mass index kg/m2 23.062.7 28.564.3a
Serum creatinine mg/dl 1.0 (0.9–1.1) 1.3 (1.1–3.9) Each patient underwent solute clearance studies at the
Creatinine clearance ml/min /1.73m2 120 (105–151) 66 (29–99)b end of the placebo run-in phase and after completion ofUrinary protein excretion rate g/24 hr ND 5.6 (0.7–13.3)b
each treatment period. Exactly the same procedure was
Data are mean 6 sd or median and range in parenthesis. Abbreviations are:
used for each patient in all functional evaluations. Clear-ND, not detectable; SBP, systolic blood pressure; DBP, diastolic blood pressure.
a P , 0.05 vs. healthy controls ance studies were also performed in a group of six volun-b P , 0.01 vs. healthy controls
teers, with normal blood pressure and no evidence of
renal disease, who served as healthy controls. The morn-
ing of the clearance studies, patients were admitted to
with the ACE inhibitor perindopril and the calcium a Metabolic Ward and submitted a 24-hour urine collec-
channel blocker nitrendipine, given in a randomized, tion for the evaluation of creatinine clearance, and uri-
cross-over design. Selected patients stopped previous an- nary urea, sodium, and total protein excretion. They were
tihypertensive therapy before study entry and during the fasting and without antidiabetic treatment from the eve-
four-week placebo run-in period were given a tablet of ning before. The last dose of placebo (end of the washout
placebo twice daily (at 8:00 a.m. and at 8:00 p.m.). period) and of the study drugs (end of the two treatment
At the end of the placebo run-in phase, patients with periods) was administered at 8:00 a.m. Blood glucose
diastolic blood pressure (DBP) . 90 and # 110 mm Hg was checked every 10 minutes and regular insulin was
(mean of 3 consecutive measurements, Korotkoff phase V, infused intravenously whenever required to maintain
taken 2 minutes apart in the sitting position after 5 min blood glucose concentration between 80 and 120 mg/dl
rest), which satisfied all the selection criteria of the study for at least two hours. Constant diuresis was induced by
protocol, including a placebo tablet compliance .80%, oral water loading. As soon as target blood glucose and
had a baseline evaluation of renal hemodynamics and
steady state diuresis were achieved, inulin, para-amino-
glomerular size-selectivity using solute clearance tech-
hippurate (PAH) and neutral dextrans clearances werenique. Patients were then randomly allocated to a 10-
performed during an euglycemic clamp, as described inweek treatment period with an ACE inhibitor (perindo-
details previously [9, 15]. Briefly, primed infusion of inu-pril, 2 mg/day at 8:00 a.m. and identical placebo at 8:00
lin and para-aminohippurate (PAH) was immediatelyp.m.) or with a calcium channel blocker (nitrendipine,
followed by a slow intravenous administration (about 1510 mg/day at 8:00 a.m. and 10 mg at 8:00 p.m.). Two
min) of Dextran-40 (130 mg/kg, Rheomacrodex, Phar-weeks after randomization, patients with DBP . 90 mm
macia, Upsala, Sweden). A sustained infusion of inulinHg had the dose of the study drugs increased as follows:
and PAH was continued throughout the study to main-4 mg/day perindopril at 8:00 a.m. and identical placebo
tain constant plasma concentrations. After an equilibra-at 8:00 p.m.; 20 mg/day nitrendipine at 8:00 a.m. and 20
tion period of about 60 minutes, three exactly timed urinemg/day at 8:00 p.m. After completion of the first 10-week
collections 30 minutes apart were made by spontaneoustreatment period, patients underwent a second clearance
voiding. To avoid loss of free PAH in glycosuric urine,study and then crossed over to the other study drug for
samples were collected over 10 ml of 4 m NaOH [16].an additional 10-week treatment period. The study drugs
Blood samples were collected at the beginning and atwere given and titrated as described above. A final clear-
the end of each clearance period. Urine and plasmaance study was then performed at completion of the
samples obtained during the first clearance period weresecond treatment period. The decision to prolong the
used to determine fractional clearance of dextran mole-treatment periods up to 10 weeks the clearance studies
cules of graded size (effective molecular radius rangingpermitted to be performed at a time when, on the basis
from 26 to 66 A˚). The same urine and plasma samplesof previously available data [8, 9], the potential residual
were used for the determination of albumin and IgGeffect of the first versus the second treatment period
concentrations. An ultrasound evaluation was per-was completely exhausted since at least four weeks, thus
formed at the end of each clearance study to verify thatminimizing the risk of a carryover effects still present at
in no case could the data be affected by incompletethe end of the treatment period. Urine collections for
evaluation of 24-hour urinary protein excretion rate were bladder emptying.
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Fig. 1. Schematic representation of the study
protocol. A description of the study design is
in the text. Symbols are: (h) 24-hour protein
excretion; ( ) clearance study.
Analytical methods (Boehringer Mannheim, Milan, Italy). Goat antihuman
albumin (American Qualex, La Miranda, CA, USA) orInulin and PAH concentrations in plasma and urine
IgG (Sigma Chimica) conjugated with alkaline phospha-samples were determined using previously described col-
tase was added, followed by alkaline phosphatase sub-orimetric assays [9, 17]. GFR was calculated as the aver-
strate (Sigma Chimica), and optical density of wells readage of the three inulin clearances. Effective renal plasma
using a micro-ELISA reader. Fractional clearances offlow (ERPF) was calculated from average PAH clear-
albumin and IgG were calculated using the same formulaance assuming a renal extraction coefficient for PAH of
employed for dextran. Other laboratory measurements0.9 for healthy controls and of 0.7 for proteinuric patients
were performed using routine laboratory techniques.with reduced GFR, as reported previously [18]. Separa-
tion of graded-size dextran molecules and inulin in plasma
Theoretical analysis of glomerularand urine samples was performed by gel permeation
membrane transportchromatography on a Sephacryl S-300 column (1.6 3 95
To investigate membrane permeability properties wecm). Column calibration was performed using dextran
analyzed glomerular sieving coefficients of test macro-standards of known molecular weight (Pharmacosmos,
molecules using a mathematical model of glomerularViby Sj., Denmark). Molecular radius of individual dex-
size-selectivity described in details previously [9, 21, 22].tran fractions was calculated according to direct mea-
This model allows separation of the effects of membranesurements of dextran reported by Oliver et al [19] that
permeability changes from glomerular hemodynamic al-relate effective molecular radii and mean molecular
terations on glomerular filtration of neutral test macro-weight of neutral dextran. Dextran and inulin concentra-
molecules. According to this model the glomerular mem-tions were assayed in the eluted fractions using colori-
brane was assumed to be perforated by cylindrical poresmetric methods previously described [9, 17, 20]. Urine-
having a lognormal distribution of their radii that is fullyto-plasma concentration ratio for inulin was calculated
described by two parameters: the mean (u) and standardfrom inulin concentrations in eluted fractions. Elution
deviation (s) of the corresponding normal distribution.volume of fractions containing inulin (molecular radius
Thus, u is a measure of the mean and s of the spread ofof 11 to 13 A˚) were identified by periodic separation of
the pore-size distribution. Besides these two parameters,a standard solution of inulin. Fractional clearance of
the model is based on another freely adjustable parame-dextran macromolecules was computed as
ter, the ultrafiltration coefficient (Kf), the product of
qD 5 (U/P)D/(U/P)IN hydraulic membrane permeability and glomerular mem-
brane-filtering surface area. We calculated Kf as ex-where (U/P)D and (U/P)IN are the urine-to-plasma con-
tended to all glomerular population in both kidneys usingcentration ratios of dextran and inulin, respectively.
the model of glomerular ultrafiltration previously de-Albumin and IgG concentrations in plasma and urine
scribed [23]. The intrinsic membrane permeability pa-samples were determined using a sensitive enzyme-linked
rameters were calculated, as shown in detail previouslyimmunosorbent assay (ELISA). Briefly, diluted samples
[9, 17], minimizing the sum of squared errors (x2) be-were placed in polystyrene wells coated with antibodies
to human albumin (Sigma Chimica, Milan, Italy) or IgG tween experimental and calculated sieving coefficients,
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in healthy controls and patients, during each individual RESULTS
clearance study. Using preliminary analysis we also per- All nine patients with baseline evaluation entered and
formed these calculations using the log-normal plus completed the crossover study. Baseline characteristics
shunt model described in details previously [22]. This of patients and of healthy controls are shown in Table 1.
model considers the glomerular capillary wall to be per- Within the limits related to difficulties in precisely estab-
forated by restrictive pores having log-normal distribu- lishing disease onset in NIDDM, patients enrolled in this
study had long-standing diabetes and a relatively goodtion of their radii and by a small fraction of large nonse-
metabolic control, on the basis of their baseline levelslective pores that act as a shunt pathway. The accuracy of
of HbA1c (Table 2). All patients reported a history ofthe two models in simulating experimental data, estimated
hypertension and were found to have mild-to-moderateusing the average sum of squared errors, was higher for
hypertension at baseline evaluation, after one monththe log-normal distribution that for the log-normal plus
washout from previous antihypertensive therapy. Theshunt model (data not shown). For this reason we
degree of renal dysfunction at study entry was heteroge-adopted the log-normal distribution model for our theo-
neous, with some patients having near-normal creatinineretical analysis.
clearances and others more advanced renal insufficiency.
However, all patients had clear evidence of severe glo-Sample size estimation and statistical analysis
merular barrier dysfunction, as documented by high uri-
The primary efficacy variable of the study was the nary protein excretion rates (in the nephrotic ranges in
fractional clearance of the largest neutral dextrans (in seven out of nine patients) and protein-creatinine ratios
particular 60 A˚ radius dextran), which most reliably re- (P/C) in spot morning urine collections (Table 2). Grizzle
flect glomerular barrier size-selectivity to plasma macro- analysis of response to perindopril and nitrendipine in
molecules. Then we predicted that the pattern of glomer- NIDDM patients [24] excluded the possibility of a carry-
ular barrier dysfunction and response to ACE inhibitor over effect between the two treatment periods on the
therapy in NIDDM patients with typical glomerulopathy main efficacy variable of the study (60 A˚ dextran frac-
would have reflected the pattern previously observed tional clearance) and on the other efficacy variables,
in IDDM patients with a comparable degree of GFR including mean sitting systolic (SBP) and diastolic (DBP)
depression and urinary proteins excretion, and a similar blood pressures, protein/creatinine ratio, 24-hour urinary
pattern of glomerular histologic changes. On the basis protein excretion rate and GFR measured at the end of
each treatment period.of this hypothesis, we predicted that in our series of
Mean sitting SBP and DBP measured before drug ad-NIDDM patients baseline fractional clearance of neutral
ministration at the end of the 10-week treatment periodsdextrans with radii of 60 A˚ would have ranged from 0.02
were significantly lowered by both perindopril and nitre-6 0.01 to 0.04 6 0.01 and would have decreased by 60%
ndipine. Actually, by the end of the perindopril treat-after ACE inhibitor therapy [9]. Power analysis based
ment, SBP and DBP were on average 19 and 11 mm Hgon these assumptions revealed that four to nine patients
lower than at baseline evaluation. Similarly, correspond-(according to the given range in neutral dextran frac-
ing blood pressure reductions after nitrendipine treat-tional clearances) were to be included to achieve a b-
ment averaged 17 and 13 mm Hg, respectively, for SBPerror of 0.10 with an a-error of 0.05.
and DBP. Comparable values were observed for SBPData are expressed as mean 6 standard deviation (sd)
and DBP at the end of perindopril or nitrendipine treat-or median and range as specified. Results of individual
ment (Table 2).groups were compared using two-tailed Student’s t-test
Renal hemodynamic parameters measured during
for unpaired data or one-way analysis of variance, as ap-
clearance studies are reported in Table 3. During the
propriate. Statistical analysis was performed using the soft- clearance studies the euglycemic condition was satisfac-
ware package StatView (Abacus Concepts Inc., Berke- torily maintained in all individual patients. Actually,
ley, CA, USA). Due to their skewed distribution, urinary blood glucose averaged 92 6 21, 88 6 17 and 102 6
protein excretion rate, albumin and IgG fractional clear- 22 mg/dl, respectively, during functional evaluation at
ance values were log-transformed before statistical anal- baseline and at the end of perindopril and nitrendipine
ysis. The statistical significance level was defined as P , treatments. As expected, GFR and ERPF were both sig-
0.05. The Grizzle approach was used to investigate the nificantly lower in diabetic patients, at baseline evalua-
possibility of a carryover effect from the first to the tion, than in normal controls. GFR and ERPF did not
second treatment periods of the study [24]. An analysis differ significantly at the end of both antihypertensive
restricted to the first treatment period was planned if a treatments. Actually, GFR showed a tendency to de-
carryover effect could not be excluded by the above crease with both perindopril and nitrendipine treat-
ments, but the differences did not reach statistical sig-approach.
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Table 2. Main clinical parameters in NIDDM patients at baseline and at the end of treatment period with perindopril or nitrendipine
Baseline Perindopril Nitrendipine
SBP mm Hg 167611 148610a 15067a
DBP mm Hg 9967 8863a 8665a
Mean AP mm Hg 12268 10864a 10765a
HbA1c % 6.461.3 6.1 61.2 6.2 61.6
Total proteins g/24 hr 5.6 (0.7–13.3) 5.0 (0.5–11.2) 5.2 (0.4–10.5)
P/C ratio 4.9 (0.4–16.5) 3.3 (0.3–7.0)b 3.5 (0.3–7.1)c
u Albumin *1023 2.4 (0.1–6.9) 2.3 (0.1–6.9) 2.4 (0.1–6.8)
u IgG *1023 0.84 (0.03–4.02) 0.59 (0.01–3.38) 0.60 (0.01–3.30)
Urea excretion g/24 hr 22.165.1 24.3 64.8 22.6 67.6
Sodium excretion mEq/24 hr 189690 172 637 199 680
Data are mean 6 sd or median and range in parentheses. Abbreviations are: AP, arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure;
u Albumin, fractional clearance of albumin; u IgG, fractional clearance of IgG.
a P , 0.01 vs. baseline
b P . 0.7 vs. baseline
c P . 0.8 vs. baseline
Table 3. Renal hemodynamic parameters in healthy controls and in NIDDM patients at baseline and at the end of the two treatment periods
Controls Baseline Perindopril Nitrendipine
GFR ml/min /1.73 m2 99.6613.4b 44.9619.9 38.2 617.0 39.7 617.2
ERPF ml/min /1.73 m2 617699a 4326196 386 6156 505 6275
FF % 1663a 1164 10 64 9 64
RVR mm Hg/ml /min /1.73 m2 7.3 (5.8–8.8)a 22.1 (7.1–48.7) 22.5 (11.0–55.3) 22.9 (5.2–82.5)
Data are mean 6 sd or median (range). Abbreviations are: GFR, glomerular filtration rate; ERPF, effective renal plasma flow; FF, filtration fraction; RVR, renal
vascular resistances.
a P , 0.05 vs. patients at baseline
b P , 0.01 vs. patients at baseline
nificance. Differences in ERPF and filtration fraction
values at the end of the two treatment periods, as com-
pared to baseline evaluation, were only numerical and
did not reach statistical significance. Baseline renal vas-
cular resistances (RVR) were significantly higher in pa-
tients, as compared to controls, and were not significantly
affected by the two study drugs.
At the end of the treatment periods, total urinary pro-
tein excretion, as well as fractional clearance of albumin
and IgG, were not significantly modified either by the
ACE-inhibitor or the Ca channel blocker (Table 2). The
mean P/C tended to decrease with both treatments but
the reduction did not reach statistical significance. Simi-
larly, neither treatment significantly affected urea and
Na1 excretion (Table 2). Fractional clearance of neutral
dextran molecules of radii ranging from 26 to 66 A˚ mea-
sured in normal controls and in diabetics are reported in
Figures 2 and 3. Sieving coefficients of dextran molecules
smaller than 40 A˚ in radius were comparable in diabetic
patients, at baseline evaluation, to those measured in
healthy controls. However, for molecules of 42 A˚ in radius
and larger, the fractional clearance measured in diabetic
patients was significantly elevated above the control
group. The effects of perindopril and nitrendipine treat-
ments on fractional clearances of dextran molecules are
Fig. 2. Fractional clearance of neutral dextrans in normal controls andreported in Figure 3. Neither drug was capable of modi-
in diabetic patients at baseline evaluation. Symbols are: (d) NIDDM
fying dextran fractional clearance to any significant ex- baseline; (h) healthy controls; *P , 0.05 vs. healthy controls; **P ,
0.01 vs. healthy controls.tent for the entire range of molecular radii investigated.
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Fig. 3. Fractional clearance of neutral dextrans in diabetic patients at the end of the treatment period with perindopril (A) and nitrendipine (B).
Symbols are: (d) NIDDM baseline; (e) NIDDM 1 perindopril; (s) NIDDM 1 nitrendipine.
Table 4. Computed glomerular ultrafiltration coefficient and membrane parameters of the lognormal pore-size distribution
r* (5%) r* (1%)
DP Kf u
mm Hg ml /min /mm Hg/1.73 m2 A˚ s A˚ x2
Controls 35 11.461.9 55.164.0 1.16 60.03 77.162.3 85.4 63.8 0.38 (0.06–1.71)
40 7.360.4 56.163.7 1.15 60.03 76.962.2 84.7 63.7 0.67 (0.06–2.17)
Basal 40 2.861.2c 60.866.3 1.16 60.05 84.8 66.1a 94.068.3a 0.39 (0.07–2.75)
45 2.160.9d 61.266.1 1.16 60.05 84.666.0b 93.568.1b 0.46 (0.06–2.88)
Perindopril 35 3.561.7 57.968.3 1.17 60.08 83.566.6 93.3 611.7 0.47 (0.13–1.00)
40 2.461.1 59.667.1 1.16 60.07 83.166.6 90.4 610.1 0.54 (0.09–1.26)
Nitrendipine 35 3.761.9 59.365.8 1.17 60.06 85.366.9 95.2 610.9 0.51 (0.08–0.84)
40 2.561.2 60.665.3 1.16 60.06 84.866.8 93.9 610.6 0.40 (0.07–0.90)
Data are mean 6 sd, or median (range). Abbreviations are: DP, transmembrane pressure difference; Kf, ultrafiltration coefficient; u, mean radius of membrane
pore radii distribution; s, standard deviation of log normal distribution; r* (5% and 1%), membrane pore radius parameters.
a P , 0.05 vs. controls (DP 5 35 mm Hg)
b P , 0.05 vs. controls (DP 5 40 mm Hg)
c P , 0.01 vs. controls (DP 5 35 mm Hg)
d P , 0.01 vs. controls (DP 5 40 mm Hg)
To definitely rule out any possibility of a confounding assumption of the transmembrane hydraulic pressure dif-
ference (DP), a parameter that cannot be measured di-carryover effect between the two treatment periods, we
also compared data at baseline and at the end of the rectly in humans. In line with previous assumptions [1, 10,
12, 22], we assumed two values of DP 5 35 and 40 mm Hgfirst treatment period only. Even in this case none of the
above parameters describing renal hemodynamics and for normal controls. For hypertensive diabetic patients,
at baseline evaluation, we considered a potential increaseglomerular barrier size-selectivity was significantly af-
fected by perindopril or nitrendipine. in DP assuming the values of 40 and 45 mm Hg. Since
experimental evidence suggests that antihypertensiveThe results of the theoretical analysis of glomerular
hemodynamics and glomerular membrane permeability treatments used in this study may lower glomerular capil-
lary pressure [25, 26], we assumed DP 5 35 and 40 mmare summarized in Table 4. This analysis is based on the
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Hg for theoretical analysis of fractional clearance data
at the end of the treatment periods.
As expected, estimates of Kf were significantly lower
in diabetic patients than in normal controls (Table 4).
On the contrary, no statistically significant changes in
Kf were induced by both antihypertensive treatments.
Calculated membrane pore-size distribution parameters
(the mean u and the standard deviation s of the log
normal probability distribution) for the control group
were remarkably similar to those previously reported
[12, 22] with an average pore-size of about 55 A˚. To
quantitate the dimensions of the largest pores, we calcu-
lated the parameters r* (5%) and r* (1%). As defined
previously [21, 27], by definition 5% and 1% of ultrafil-
Fig. 4. Fraction of filtrate as a function of pore radii [r4g (r)] in healthy
trate permeates pores larger than r* (5%) and r* (1%), controls and in diabetic patients at baseline evaluation and at the end
of perindopril and nitrendipine treatment.respectively. For healthy controls these two parameters
averaged approximately 77 A˚ and 85 A˚, respectively. In
line with previous investigations [25, 26], membrane pore
parameters did not change importantly for the two as-
ance of large dextrans was significantly elevated oversumed values of DP. In diabetic patients the mean pore
control values.size (u) averaged more than 60 A˚; however, the differ-
To establish to what extent the altered fractional dex-
ence above controls did not reach statistical significance.
tran clearance was due to effective permeability changes
No significant changes were observed for the spread of or to changes in glomerular hemodynamics, we adopted
the pore-size distribution (s). On the contrary, r* (5%) a theoretical analysis based on the assumption that glo-
and r* (1%) were significantly elevated in diabetic pa- merular membrane is perforated by pores having a log-
tients at baseline evaluation than in normal controls. normal probability distribution of their radii [9, 17, 22].
Actually, in diabetic patients r* (5%) and r* (1%) were The agreement between experimental values and theo-
on average more than 7 A˚ larger than corresponding retical estimates obtained with this distribution was
radii of normal controls. Neither antihypertensive treat- good, as shown by the sum of squared errors (x2) re-
ment significantly affected the membrane pore-size dis- ported in Table 4. On average an error of 17% was
tribution parameters [u and s, r* (5%) and r* (1%)]. calculated for the entire sieving curve in the worst cases.
Values of u, r* (5%) and r* (1%) were numerically As mentioned previously, the log normal distribution
lower at the end of perindopril treatment than at baseline fitted the experimental data better than the log normal
evaluation, but the differences did not reach statistical plus shunt model, and this seems to depend on the shape
significance. of the sieving profiles shown in Figures 2 and 3. Actually,
sieving coefficients in normal controls and in NIDDM
patients decrease linearly for the largest test macromole-DISCUSSION
cules without the tendency to become flat that has been
Data are available that IDDM patients with overt ne- reported for sieving coefficients in nephrotic patients
phropathy have a defect in glomerular size-selectivity [31]. This sieving profile is better simulated by the as-
[1–4]. Studies of this kind in NIDDM patients with overt sumption of a parallel shunt pathway. Our present re-
nephropathy are lacking. Here we investigated renal he- sults, however, are in line with those obtained by Myers
modynamics and glomerular size-selective function in and coworkers in NIDDM, who showed a linear trend
patients with NIDDM and renal biopsy findings of pure for sieving coefficient of the largest dextrans and as-
diabetic-type glomerulopathy. The results indicated that sumed the log normal distribution of pore radii to simu-
NIDDM patients with overt nephropathy have lower late dextran fractional clearance [13].
GFR and ERPF and a decreased ultrafiltration coeffi- As shown in Figure 4, in the diabetic group distribution
cient as compared to healthy controls. By contrast, renal function of pore-sizes was on average shifted towards
vascular resistances were significantly increased in dia- larger pores, as compared to normal controls. We calcu-
betics as compared to healthy controls. The differences lated a mean pore-size (u) radius of 5 A˚ greater in NIDDM
cannot be attributed to age since in normotensive, nondi- patients than in controls (Table 4), and despite the differ-
abetic subjects these parameters are not affected by age ence it did not reach statistical significance due to the
[28–30]. We also found a glomerular size-selective dys- large variability of this parameter in diabetics. Dimen-
sions of the largest pores were also remarkably differentfunction in NIDDM to the extent that fractional clear-
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in the two groups. Calculations showed that while 1% cannot be attributed to the small number of patients,
since the study was designed a priori for a 90% power toof filtrate permeated pores larger than 84 A˚ in diabetic
patients, the corresponding radius for normal controls detect a 60% reduction in 60 A˚ neutral dextran fractional
clearance (the primary efficacy variable of the study)was only an average of 77 A˚. We speculate that in diabet-
ics the circulating plasma proteins are more freely filtered as statistically significant (P , 0.05) at the end of the
perindopril treatment as compared to the predicted base-throughout these pores than in controls.
Similar findings have been reported in IDDM [3, 5] line. Values of 60 A˚ dextran fractional clearance at base-
line were found within the predicted ranges that wereand in nondiabetic proteinuric glomerulopathies [32–35].
Several lines of research have consistently indicated that assumed for the sample size estimation. After perindo-
pril, the neutral dextran sieving profile was not differentincreased glomerular filtration of albumin and IgG in
disease conditions is the consequence of a selective in- from basal levels, indicating that, at variance with IDDM,
ACE inhibitors are unable to correct size-selective dys-crease in the amount of ultrafiltrate permeating large
unrestrictive membrane pores, which collectively form function of the glomerular membrane in NIDDM. Fail-
ure of ACE inhibitor therapy to significantly affect bar-the so-called “shunt pathway.” That IDDM and NIDDM
share a common pathway of size-selective dysfunction rier dysfunction of patients with NIDDM and a renal
biopsy finding of diabetic nephropathy are consistent withis in harmony with the studies of Myers and coworkers in
Pima Indians, who found that glomerular hemodynamic the negligible effect of perindopril on urinary protein
excretion rate. Urinary proteins were quantitated in allchanges and loss of size-selectivity were independent of
the type of diabetes [36]. Moreover, comparison of frac- patients on two separate occasions, two weeks apart, at
the end of each treatment period to minimize variationstional clearance of charged proteins like albumin with that
of neutral dextrans can be taken to indicate a concomitant associated with diet protein intake, blood glucose and
blood pressure. Not only was the ACE inhibitor unabledefect of glomerular charge- and size-selective function
operating in NIDDM. On the basis of the data recently to improve dextran sieving coefficient in our setting, but
the calcium channel blocker was equally ineffective onreported by Blouch et al on sieving coefficient of dextran
and ficoll, the 42 to 44 A˚ dextran molecule is probably sieving coefficient and urinary proteins. Why did neither
treatment ameliorate glomerular size-selective functionthe most comparable to albumin in terms of molecular
size [31]. Despite the fact that the size of albumin is about and limit urinary protein excretion in NIDDM as op-
posed to IDDM and other nondiabetic proteinuric ne-36 A˚ in radius, it has been shown that elongated dextran
molecules permeate the membrane more freely than phropathies [4, 17]? Doses of the ACE inhibitor and
duration of treatment were comparable to those usedglobular macromolecules [31, 37]. Our present data
showing that sieving coefficient of 42 and 44 A˚ dextran by others in IDDM [8, 9], and were found to be effective
in ameliorating size-selectivity and reducing proteinuria.are significantly higher in IDDM patients than in controls
(Fig. 2) would indicate that a size-selectivity defect is at The only possible explanation for this apparent inconsis-
tency is that renal structural changes in our NIDDMleast in part responsible for abnormal glomerular filtra-
tion of albumin. On the other hand, a charge-selective patients were very advanced and diffuse, involving thick-
ening of the basement membrane, broadening of the footdysfunction is likely to contribute to the 55 to 75% in-
crease in transmembrane passage of 42 to 44 A˚ dextran processes, and diffuse sclerotic changes. It is tempting to
speculate that these type of glomerular structural lesionswe found in patients, as compared to normal controls.
Such an increase alone is too limited to account for the that develop with time in NIDDM patients can reach an
extent that prevents pharmacological treatments fromincrease in albumin filtration that, on the basis of the
observed albumin fractional clearance, exceeded at least achieving the desired effect on membrane sieving func-
tional properties.two orders of magnitude. Thus, concomitant changes in
charge- and size-selectivity function are likely to contrib- Thus, despite the biopsy finding of pure diabetic ne-
phropathy, the same level of renal insufficiency and theute to albuminuria in NIDDM.
Concerning the effect of ACE inhibition on size-selec- same defect in dextran’s clearance, the response to ACE
inhibition in NIDDM versus IDDM patients appears totive properties of glomerular membrane, we and others
have consistently found that in patients with IDDM these be different. These results may have clinical relevance.
The large majority of diabetics with overt nephropathycompounds consistently ameliorated size-selective dys-
function [8, 9] and, as expected, reduced urinary excre- indeed suffer NIDDM. Today, on the basis of the results
of ACE inhibition treatment obtained in IDDM [38],tion of total proteins and limited fractional clearance of
albumin and IgG. At variance, ACE inhibition did not more and more patients with NIDDM are given ACE
inhibitors by analogy. However, the few controlled stud-ameliorate glomerular barrier function to any significant
extent, nor influence urinary protein excretion in patients ies in NIDDM patients available thus far, with an ade-
quate follow-up and measured GFR, consistently failedwith NIDDM taking part in the present study. Failure to
detect an effect on test macromolecules sieving profiles to document any specific effect of ACE inhibition ther-
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and improves glomerular size-selectivity of nephrotic patients withapy [39–41]. Even studies in hypertensive NIDDM pa-
idiopatic membranous nephropathy. (abstract) J Am Soc Nephrol
tients at an earlier stage of renal disease (incipient ne- 8:93, 1997
5. Nakamura Y, Myers BD: Charge selectivity of proteinuria in dia-phropathy) failed to document that ACE inhibitors were
betic glomerulopathy. Diabetes 37:1202–1211, 1988better than other therapies [42–44], in contrast with a
6. Benigni A, Zoja C, Remuzzi G: The renal toxicity of sustained
previous report in which ACE inhibitor therapy pre- glomerular protein traffic. Lab Invest 73:461–468, 1995
7. Benigni A, Remuzzi G: Glomerular protein trafficking and pro-vented a progressive increase in urinary albumin excre-
gression of renal disease to terminal uremia. Semin Nephrol 16:151–tion and delayed the onset of overt nephropathy in nor-
159, 1996
motensive microalbuminuric NIDDM patients [45]. 8. Morelli E, Loon N, Meyer TW, Peters W, Myers BD: Effects
of converting-enzyme inhibition on barrier function in diabeticIn summary, our present data document that NIDDM
glomerulopathy. Diabetes 39:76–82, 1990patients with pure diabetic-type glomerulopathy and
9. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G, Re-
overt proteinuria have a pattern of glomerular barrier muzzi G: Effect of low-dose enalapril on glomerular size-selectivity
in human diabetic nephropathy. J Nephrol 6:36–43, 1993dysfunction that closely resembles previous findings in
10. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction inIDDM in comparable patient series. In NIDDM, at vari-
albuminuria predicts diminished progression in diabetic nephropa-
ance with IDDM, however, glomerular size-selective thy. Kidney Int 45(Suppl):S145–S149, 1994
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect ofdysfunction and proteinuria was neither ameliorated by
angiotensin-converting-enzyme inhibition on diabetic nephropa-ACE inhibition nor by dihydropyridinic calcium channel
thy. N Engl J Med 329:1456–1462, 1993
blockade. These data provide the physiopathological 12. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of
different antihypertensive drugs in human diabetic nephropathy:framework to understand the apparently lower renopro-
An updated meta-analysis. Nephrol Dial Transplant 10(Suppl):39–tection offered by ACE inhibitors in NIDDM as com-
45, 1995
pared to IDDM patients, and are in line with other pre- 13. Myers BD, Nelson RG, Tan M, Beck GJ, Bennet PH, Knowler
WC, Blouch K, Mitch WE: Progression of overt nephropathy inliminary studies [36, 43]. On the other hand, our findings
non-insulin-dependent diabetes. Kidney Int 47:1781–1789, 1995were obtained in a relatively small number of patients
14. Gambara V, Mecca G, Remuzzi G, Bertani T: Heterogeneous
and need confirmation in large scale, long-term clinical nature of renal lesions in type II diabetes. J Am Soc Nephrol
3:1458–1466, 1993trials. In the meantime, differences in the response to
15. Remuzzi A, Viberti G, Ruggenenti P, Battaglia C, Pagni R,ACE inhibitors in NIDDM versus IDDM suggest that
Remuzzi G: Glomerular response to hyperglycemia in human dia-
it is at least premature to extend the use of ACE inhibi- betic nephropathy. Am J Physiol 259:F545–F552, 1990
16. Dalton RN, Wiseman MJ, Turner C, Viberti GC: Measurementtors to all diabetics based on results of trials in IDDM.
of urinary para-aminohippuric acid in glycosuric diabetics. KidneyIf one considers the high prevalence of renovascular
Int 34:117–120, 1988
disease, and the risk of ACE inhibitor-associated acute 17. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M,
Remuzzi G: Angiotensin converting enzyme inhibition improvesrenal failure and life-threatening hyperkalemia in this
glomerular size-selectivity in IgA nephropathy. Kidney Int 39:1267–setting, the drawbacks of such an approach appear ob-
1273, 1991
vious. 18. Battilana C, Zhang H, Olshen R, Wexler L, Myers BD: PAH
extraction and the estimation of plasma flow in the diseased human
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